Wei Peng Yong
Overview
Explore the profile of Wei Peng Yong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
114
Citations
3480
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Blasiak A, Truong A, Foo N, Tan L, Kumar K, Tan S, et al.
NPJ Precis Oncol
. 2025 Feb;
9(1):49.
PMID: 39984618
In oncology, the conventional reliance on the maximum tolerated dose (MTD) strategy for chemotherapy may not optimize treatment outcomes for individual patients. CURATE.AI is an AI-derived platform that utilizes a...
2.
Ma H, Srivastava S, Ho S, Xu C, Lian B, Ong X, et al.
Cancer Discov
. 2025 Jan;
PMID: 39774838
Gastric cancer (GC) is a major cause of global cancer mortality with high levels of heterogeneity. To explore geospatial interactions in tumor ecosystems, we integrated 2,138 spatial transcriptomic regions-of-interest (ROIs)...
3.
Provenzano L, Gwee Y, Conca V, Lonardi S, Bozzarelli S, Tamburini E, et al.
Ther Adv Med Oncol
. 2024 Nov;
16:17588359241289517.
PMID: 39502404
Background: Ascites is common in advanced gastrointestinal cancers with peritoneal metastases (PM) and negatively impacts patient survival. No study to date has specifically evaluated the relationship between ascites, PM and...
4.
Shimura M, Matsuo J, Pang S, Jangphattananont N, Hussain A, Rahmat M, et al.
Gut
. 2024 Oct;
74(3):364-386.
PMID: 39438124
Background: The elevation of IQGAP3 expression in diverse cancers indicates a key role for IQGAP3 in carcinogenesis. Although IQGAP3 was established as a proliferating stomach stem cell factor and a...
5.
Lordick F, Rha S, Muro K, Yong W, Obermannova R
Cancers (Basel)
. 2024 Oct;
16(19).
PMID: 39409957
The prognosis of patients diagnosed with locally advanced and metastatic gastric and esophago-gastric junction cancer is critical. The optimal choice of systemic therapy is essential to optimize survival outcomes. :...
6.
Zhao J, Ong C, Srivastava S, Chia D, Ma H, Huang K, et al.
Gastroenterology
. 2024 Aug;
167(7):1384-1398.e4.
PMID: 39147169
Background & Aims: Peritoneal metastasis (PM) in gastric cancer (GC) is associated with poor prognosis and significant morbidity. We sought to understand the genomic, transcriptomic, and tumor microenvironment (TME) features...
7.
Walsh R, Ong R, Cheo S, Low P, Jayagopal A, Lee M, et al.
Front Oncol
. 2024 May;
14():1342346.
PMID: 38812774
Introduction: Molecular profiling of metastatic breast cancer (MBC) through the widespread use of next-generation sequencing (NGS) has highlighted actionable mutations and driven trials of targeted therapy matched to tumour molecular...
8.
Yu J, Li M, Ren B, Cheng L, Wang X, Ma Z, et al.
Front Pharmacol
. 2023 Sep;
14:1261575.
PMID: 37719852
Hepatocellular carcinoma (HCC) is a prevalent primary liver cancer, representing approximately 85% of cases. The diagnosis is often made in the middle and late stages, necessitating systemic treatment as the...
9.
Koh B, Tan D, Lim W, Wong J, Ng C, Chan K, et al.
Oncoimmunology
. 2023 Jun;
12(1):2214478.
PMID: 37284696
The use of immune checkpoint inhibitors (ICIs) targeting PD-L1/PD-1 and CTLA-4 has transformed the oncology practice of hepatocellular carcinoma. However, only 25-30% of the patients with advanced HCC treated with...
10.
Xu C, Huang K, Law J, Chua J, Sheng T, Flores N, et al.
Gut
. 2023 Mar;
72(9):1651-1663.
PMID: 36918265
Objective: Gastric cancer (GC) is a leading cause of cancer mortality, with being the second most frequently mutated driver gene in GC. We sought to decipher -specific GC regulatory networks...